Rhenium-188 P 2045
Alternative Names: BAY-865284; NeoTide; P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188 P2045; TozarideLatest Information Update: 28 Apr 2021
Price :
$50 *
At a glance
- Originator Bayer Schering Pharma
- Developer Andarix Pharmaceuticals
- Class Antineoplastics; Heavy metals; Peptides; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Somatostatin receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Small cell lung cancer
- No development reported Pancreatic cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (IV)
- 15 Apr 2019 Rhenium-188 P 2045 is still in phase I/II trials for Non-small cell lung cancer in USA (Andarix website, April 2019)
- 15 Apr 2019 Rhenium-188 P 2045 is still in preclinical trials for pancreatic cancer in USA (Andarix website, April 2019)